Adults aged ≥60 years who have medical conditions that increase their risk of severe RSV disease are recommended to receive RSV vaccine

A single dose of RSV vaccine is recommended for adults aged ≥60 years with risk factors for severe RSV disease. See Table. Conditions associated with increased risk of severe RSV disease in adults.

RSV vaccine may be given at any time of the year but, where possible, should be offered before the start of the RSV season, which typically occurs from April to September. Adults recommended to receive an RSV vaccine, who have previously had an RSV infection, can receive it once they are recovered.

Either Abrysvo or Arexvy may be used, with no brand preference.

Protection lasts for at least 2 years. Recommendations on revaccination will be updated when data become available.